This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (120)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Geertrui F. Vanhove, MD, PhD; Jonathan M. Schapiro, MD; Mark A. Winters, MSc; Thomas C. Merigan, MD; Terrence F. Blaschke, MD
Stanford University Stanford, Calif

JAMA. 1996;276(24):1955-1956.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—We conducted a 2-dose study of saquinavir in which 40 human immunodeficiency virus type 1 (HIV-1)positive patients received either three or six 200-mg capsules of saquinavir (Roche Products, Welwyn, United Kingdom) 6 times daily (total dose, 3600 mg/d or 7200 mg/d).¹ Analysis of an early cohort of patients enrolled in the study demonstrated that the duration of the response as measured by HIV-1 plasma RNA copy number varied widely within the 2 groups. This variation was not accounted for by the development of resistant mutations alone.

To investigate whether decreased patient compliance with this intensive regimen could explain the observed variation in viral responses, we monitored drug-taking behavior in the remaining patients on their enrollment into the high-dose group for the initial 24 weeks of therapy using medication container closures or caps that record the precise date and time of the opening and closing of the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?